At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g., fenofibrate, bezafibrate, or a salt thereof) and an HMG-CoA reductase inhibitor (e.g. , a statin compound, for example, pravastatin, atorvastatin, or salts thereof) is, as active ingredients, combined with an a-glucosidase inhibitor (e.g. , voglibose, and acarbose) in the pharmaceutical composition of the present invention. The proportion of the ±-glucosidase inhibitor may be about 0.001 to 50 parts by weight relative to 100 parts by weight of the hyperlipidemic agent. The present invention provides a pharmaceutical composition which is excellent in prophylactic and/or therapeutic effect on metabolic syndrome, hyperlipemia, diabetes, diabetes complications, etc, and has few side effects.
